Role of cMET in the development and progression of colorectal cancer by J.C.S. P&#233 et al.
Int. J. Mol. Sci. 2013, 14, 18056-18077; doi:10.3390/ijms140918056 
 
International Journal of  
Molecular Sciences 
ISSN 1422-0067  
www.mdpi.com/journal/ijms 
Review 
Role of cMET in the Development and Progression of  
Colorectal Cancer 
Juan Carlos Samamé Pérez-Vargas 1, Pamela Biondani 2, Claudia Maggi 2, Manuela Gariboldi 3,4, 
Annunziata Gloghini 5, Alessandro Inno 6, Chiara Costanza Volpi 5, Ambra Vittoria Gualeni 5, 
Maria di Bartolomeo 2, Filippo de Braud 2, Alessandra Castano 2, Ilaria Bossi 2 and  
Filippo Pietrantonio 2,* 
1 Medical Oncology Department, Arnau de Vilanova Universitary Hospital, 25198 Lleida, Spain;  
E-Mail: jcspv@hotmail.com 
2 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 
1-20133 Milan, Italy; E-Mails: pamela.biondani@istitutotumori.mi.it (P.B.); 
claudia.maggi@istitutotumori.mi.it (C.M.); maria.dibartolomeo@istitutotumori.mi.it (M.B.); 
filippo.debraud@istitutotumori.mi.it (F.B.); alessandra.castano@istitutotumori.mi.it (A.C.); 
ilaria.bossi@istitutotumori.mi.it (I.B.)  
3 Experimental Oncology and Molecular Medicine Department,  
Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian,  
1-20133 Milan, Italy; E-Mail: manuela.gariboldi@istitutotumori.mi.it 
4 FIRC Institute of Molecolar Oncology Foundation (IFOM), 1-20133 Milan, Italy 
5 Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian,  
1-20133 Milan, Italy; E-Mails: annuziata.gloghini@istitutotumori.mi.it (A.G.); 
chiara.volpi@istitutotumori.mi.it (C.C.V.); ambra.gualeni@istitutotumori.mi.it (A.V.G.) 
6 Medical Oncology, Sacro Cuore-Don Calabria Hospital, 37024 Negrar (Verona), Italy;  
E-Mail: alessandro.inno@gmail.com 
* Author to whom correspondence should be addressed;  
E-Mail: filippo.pietrantonio@istitutotumori.mi.it; Tel.: +39-22-390-3807; Fax: +39-22-390-2149. 
Received: 25 July 2013; in revised form: 13 August 2013 / Accepted: 27 August 2013 /  
Published: 3 September 2013 
 
Abstract: Mesenchymal-epithelial transition (MET) is a member of a distinct subfamily of 
heterodimeric receptor tyrosine kinase receptors that specifically binds the hepatocyte 
growth factor (HGF). Binding to HGF leads to receptor dimerization/multimerization and 
phosphorylation, resulting in its catalytic activation. MET activation drives the malignant 
progression of several tumor types, including colorectal cancer (CRC), by promoting 
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signaling cascades that mainly result in alterations of cell motility, survival, and 
proliferation. MET is aberrantly activated in many human cancers through various 
mechanisms, including point mutations, gene amplification, transcriptional up-regulation, 
or ligand autocrine loops. MET promotes cell scattering, invasion, and protection from 
apoptosis, thereby acting as an adjuvant pro-metastatic gene for many tumor types. In 
CRC, MET expression confers more aggressiveness and worse clinical prognosis. With all 
of this rationale, inhibitors that target the HGF/MET axis with different types of response 
have been developed. HGF and MET are new promising targets to understand the 
pathogenesis of CRC and for the development of new, targeted therapies. 
Keywords: colorectal cancer; hepatocyte growth factor; mesenchymal-epithelial transition 
factor; pathogenesis; prognosis 
 
1. Introduction 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and 
represents the most frequent gastrointestinal malignancy in Western countries [1]. Despite the 
advances in the management of CRC, about 30% of patients eventually develop distant metastases 
after curative surgery, even when treated with adjuvant chemotherapy and/or radiotherapy. The 
molecular biology of CRC has been widely studied [2]; however, the validation of biomarkers, which 
may help to predict regional and distant invasion, is still an unmet clinical need. 
The mesenchymal-epithelial transition (MET) gene was discovered in 1984 in a human cell line of 
osteogenic sarcoma treated with the chemical carcinogen N-methyl-N-nitro-N-nitrosoguanidine [3]. 
MET oncogene is activated by the translocated promoter region (TPR), which translocates from 
chromosome 1 to the region upstream of the MET gene, on chromosome 7. The resulting TPR-MET 
fusion protein shows constitutively-active MET kinase activity [3,4]. 
During the same decade, a potent mitogen for parenchymal liver cells, the hepatocyte growth factor 
(HGF), was isolated in human plasma and murine platelets [5]. In addition, Stoker et al. [6] described 
the fibroblast-derived epithelial motility factor, or scatter factor (SF), a protein expressed by 
fibroblasts and smooth muscle cells that induces motility of epithelial cells [3]. Subsequent studies 
identified HGF and SF as the same protein (HGF/SF) [7]. Noteworthy, the MET proto-oncogene 
encodes for cMET, a receptor with tyrosine-kinase activity the only known ligand for which is  
HGF [8,9]. 
The cMET-HGF/SF pathway plays a crucial role in several biological activities such as motility, 
proliferation, cell survival, embryogenesis, angiogenesis, and wound healing [10–12]. However, this 
pathway is also involved in the development and metastatic progression of many different tumor types, 
including CRC and gastric cancer, ovarian cancer, head and neck squamous cell carcinoma, lung 
cancer, and hereditary and sporadic papillary renal cancer [13–18]. 
This review provides an update of the most significant preclinical and clinical data on the role of 
cMET in the development of CRC, exploring its possible use as prognostic biomarker and its potential 
applications as a predictive factor for pharmacological interventions. 
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2. Literature Search Methodology 
For this review, the PubMed database was searched for articles concerning cMET as a biomarker 
for CRC and published in English before April 2013; early-release publications were also considered 
for inclusion. We used the search terms “colorectal cancer” AND “MET”. Preclinical and clinical 
studies were eligible if they evaluated the association of cMET with pathogenesis, pathological 
features, prognosis, or prediction of treatment outcomes in CRC, according to Authors’ judgment. 
3. Characteristics of MET and Its Role in CRC 
3.1. Molecular Biology of HGF/cMET Axis 
The MET gene is located on chromosome 7 (bands q21–q31) and consists of 21 exons separated by 
20 introns [19,20]. The extracellular domain of cMET presents two subunits, linked by a disulphide 
bond, which form the mature receptor for HGF. The intracellular domain is constituted of a 
juxtamembrane domain, involved in the receptor down-regulation, a tyrosine kinase domain, involved 
in signal transduction, and a C-terminal regulatory tail (Figure 1) [9,21]. 
Figure 1. HGF/cMET signaling pathways. HGF–SF binds to and results in dimerization 
and activation of the c-Met kinase domain. The Tyr residues in the docking sites are then 
phosphorylated. Effector molecules such as GRB2, GAB1, SHP2, SOS, PLC, and SRC are 
recruited and activate a variety of downstream signaling cascades, chiefly the ERK–MAPK 
and the PI3K–AKT pathways.  
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cMET belongs to a heterodimeric receptor tyrosine kinase family, which includes the macrophage 
stimulating 1 receptor and has homology with semaphorins and plexins [22]. The cMET-related 
tyrosine kinase family also shares homology with the human insulin receptor [9]. cMET is 
physiologically expressed in epithelial cells, but is also found in vascular and lymphatic endothelial 
cells [23,24], as well as neural cells, hepatocytes, hematopoietic cells, and perycites [25–28]. 
HGF belongs to the plasminogen-related growth factor family. The HGF gene is composed of 
70,000 base pairs (18 exons and 17 introns) and is located on chromosome 7q21.1. HGF protein 
belongs to the plasminogen-related growth factor family and it is expressed by cells of mesenchymal 
origin or by tumor cells through autocrine mechanism [10,29].  
As shown in Figure 1, the activation of HGF/cMET pathway begins with the autophosphorylation 
of tyrosine residues of the intracellular region of cMET (Y1230, Y1234, Y1235) [30]. Further 
autophosphorylations on Y1349 and Y1356, two tyrosine residues near the COOH tail, form a 
multifunctional docking site that recruits intracellular adapters via SRC homology-2 domains and other 
recognition motifs, thus, initiating downstream signaling. Several proteins and kinase substrates, such 
as growth factor receptor-bound protein 1 (GRB1) and 2 (GRB2), phosphatidylinositol 3-kinase 
(PI3K), and v-src sarcoma viral oncogene homolog (SRC), act as adaptors [31,32]. In details, GRB1 
tyrosyl phosphorylation by the cMET tyrosine kinase leads to the recruitment of PI3K, which in turn 
binds to cMET through its p85 subunit, and contributes to cell cycle progression, inhibition of 
apoptosis, and cellular motility [33]. 
3.2. Biological Activity of HGF/cMET Axis 
The HGF/cMET pathway is related to many cellular and biological processes, as summarized in 
Table 1. 
Embryogenesis. MET contributes to the migration and development of muscle tissue by controlling 
the epithelial-mesenchymal transition (EMT) of myogenic progenitor cells, and to the development of 
neuronal precursors, liver, and placental tissue. In fact, an animal study in mice knocked-out for either 
HGF or MET, or both, resulted in embryonic lethality [34]. 
Tissue regeneration. MET and HGF genes were reported to be up-regulated after injury in different 
epithelial tissues, such as kidney, lung, skeletal muscle, heart, skin, and liver. In the skin, MET was 
shown to be essential for wound repair [27]. In the liver, it was observed that the activation of the 
HGF/cMET pathway is essential for DNA synthesis and liver regeneration [35], while, on the other 
hand, MET ablation resulted in impaired proliferation and incomplete liver regeneration [36]. This 
suggests a role for MET in the protection against tissue damage and in tissue repair [12,18,31].  
Cell proliferation and survival. HGF/cMET pathway was shown to provide tumor cells with a 
proliferative advantage, through the tyrosine phosphorylation of the focal adhesion kinase (FAK) and 
the downstream activation of cell proliferation, survival, and migration [37]. 
Cytoskeleton. HGF/cMET pathway induces tyrosine phosphorylation of paxillin, a protein involved 
in cell adhesion, actin reorganization, and cell growth [3,30]. 
Scattering and cell motility. HGF/cMET pathway increases cell motility, invasion, and, ultimately, 
metastases by acting on the cytoskeleton. PI3K is an important molecule in HGF-induced mitogenesis, 
morphogenesis, and chemotaxis [3,10,30,38,39]. 
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Table 1. Cellular and biological processes related to the HGF/cMET pathway. 
Cellular/biological process HGF/cMET pathway involvement 
Embryogenesis EMT of myogenic progenitor cells and development of muscular tissue 
Development of neuronal precursors, liver and placental tissue 
 Regeneration after injury in different epithelial tissues 
Tissue regeneration Wound repair of the skin 
Induction of DNA synthesis and liver regeneration  
Cell proliferation and survival Activation of cell proliferation, survival and migration  
Cytoskeleton Involvement in cell adhesion, actin reorganization and cell growth  
Scattering and cell motility Induction of cell motility, invasion and metastatization 
Abbreviations: EMT, epithelial-mesenchymal transition; HGF, hepatocyte growth factor; MET, mesenchymal-epithelial transition. 
3.3. cMET Signaling Pathway and Angiogenesis 
The HGF/cMET signaling pathway plays a role in angiogenesis and lymphangiogenesis by 
promoting the growth of endothelial cells, increasing the expression of pro-angiogenic mediators, such 
as vascular endothelial growth factor (VEGF), and suppressing the activity of thrombospondin 1—a 
negative regulator of angiogenesis [23,40]. 
cMET activates several pathways including SRC/FAK, the signal transducer and activator of 
transcription 3 (STAT3), PI3K/AKT, and RAS [3,10]. These signaling pathways may stimulate 
endothelial cells both directly—by mitogenic or morphogenic activity—and indirectly by regulating 
other pro-angiogenic factors [40]. 
Hypoxia is a key regulator of cMET, as it induces the expression of the transcription factor hypoxia 
inducible factor 1 alfa (HIF-1α). The existence of this correlation is supported by preclinical studies in 
mouse xenograft models, which showed that the therapeutic inhibition of angiogenesis reduces tumor 
vascularization and causes hypoxia, and therefore may promote cMET-mediated invasion of malignant 
cells [41,42]. 
Considering that the relevant role of MET in angiogenesis is combined—in a synergic fashion—with 
the effect exerted by the VEGF/VEGFR pathway, novel therapeutic strategies, which focus on the 
simultaneous blockade of both pathways, have been recently proposed [43]. 
3.4. cMET and Other Growth Factor Receptors 
The HGF/cMET axis presents several cross-talks with other growth factor receptors, such as the 
epidermal growth factor receptor (EGFR), the insulin growth factor receptor 1 (IGF1R), and the 
recepteur d’origine Nantais (RON). These cross-talks may help the understanding of the mechanisms 
of resistance to targeted therapies [44]. 
Specifically, the cross-talk between cMET and epidermal growth factor receptor (EGFR) is 
implicated in tumorigenesis. Jo et al. [45] reported that cMET is activated directly by the transforming 
growth factor alfa (TGFα) and EGFR in an autocrine fashion; however, indirect activation is also 
possibly induced by EGFR blockade. MET signaling also activates cells resistant to EGFR tyrosine 
kinase inhibitors. In non-small-cell lung cancer (NSCLC), Engelman et al. [46] showed that cMET 
amplification could explain the resistance to EGFR tyrosine kinase inhibitors, such as gefitinib.  
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Liska et al. [47] showed that EGFR and cMET are co-expressed in CRC cell lines, and act 
synergistically to increase proliferation. It is well known that therapeutic strategies for CRC have 
focused on the development of anti-EGFR monoclonal antibodies (MoAbs)—such as cetuximab and 
panitumumab [48,49]. The emergence of resistance to cetuximab was explained by HGF-mediated 
activation of cMET, with increased signaling through the PI3K/AKT and mitogen-activated protein 
kinase (MAPK) pathways. Therefore, dual blockade of cMET and EGFR may be synergistic in the 
treatment of CRC [47]. 
The HGF/cMET axis presents a well-established cross-talk with IGF1 and its receptor IGF1R, which 
are both implicated in the development and progression of a variety of human cancers. Bauer et al. [50] 
demonstrated that IGF1R and cMET contribute synergistically in human CRC cells to the activation of 
the urokinase plasminogen activator and its receptor, which are mediators of migration and invasion. In a 
recent study, Varkaris et al. [51] proved that IGF1 expression is sufficient to induce MET activation  
in vivo in a xenograft model. In multiple cell lines, IGF1-mediated MET activation suggests that this 
cross-talk may contribute to progression in several cancer types when both molecules are expressed. 
This finding suggests that MET may be activated by multiple tyrosine kinase receptors, and may 
therefore be an important therapeutic target [51]. 
RON is a member of the MET tyrosine kinase receptor family, which is associated with resistance 
to apoptosis, production of superoxide anions, and phagocytosis of macrophages. Therefore, it 
stimulates pro-oncogenic signaling pathways such as SRC and PI3K/AKT [52]. The cross-talk 
between cMET and RON was documented in a number of experimental models, and was confirmed in 
human cancers including liver, pancreas, breast, and bladder carcinomas [53]. In hepatocellular 
carcinoma, some cytokines, including epidermal growth factor (EGF), interleukin1, interleukin6, and 
TNFα, are able to induce the expression of both cMET and RON, thus suggesting that MET and RON 
are regulated by similar cytokine networks [54]. RON/cMET heterodimerization plays a key role in the 
activation of related signal transduction pathways. Follenzi et al. [54] showed that the formation of the 
heterodimeric complexes leads to reciprocal transphosphorylation on tyrosine residues of the two 
receptors, therefore resulting in the activation of their catalytic regions. In particular, not only is RON 
specifically phosphorylated by an activated form of cMET, but the presence of MET-specific inhibitors 
suppresses RON phosphorylation.  
3.5. MET Mutation and Deregulation 
Aberrant HGF/cMET signaling pathway was described in several solid tumors. The mutation of 
MET, located in the tyrosin-kinase domain, was first described in type 1 hereditary papillary renal 
carcinoma and in sporadic papillary renal carcinoma [55]. MET mutations may also, rarely, be 
oncogenic drivers in metastatic head and neck cancer [15], gastric cancer [16], liver cancer [36], and 
NSCLC [17]. Other mutations can also be found in different regions of cMET, such as the iuxtamembrane 
region, and result in the receptor’s up-regulation—as was shown in 12% of NSCLC [17,31]. 
MET mutations, overexpression of HGF or cMET, and co-expression of both HGF/SF and MET by 
the same cell, can all contribute to tumorigenesis. In fact, cell lines overexpressing cMET present a 
highly invasive and metastatic potential [37], due to the up-regulation of urokinase-type plasminogen 
activator and matrix metalloproteinases [56]. Other mechanisms include the induction of angiogenesis, 
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lymphangiogenesis, and the prevention of apoptosis through the phosphorylation of PI3K and 
subsequent AKT activation [30,57]. HGF overexpression appears to be related to the invasion and 
migration of tumor cells, mainly through the p42/p44 MAPK pathway, which enhances cellular 
proliferation, promoting the EMT [58]. In vitro studies showed that the induction of increased HGF 
levels stimulates the invasiveness of Caco-2 CRC, by promoting cell motility and proteases synthesis [59]. 
4. Methods of cMET Assessment 
The oncogene MET can be studied both at the protein and gene levels. In order to investigate the 
protein expression, immunohistochemistry (IHC) represents a reliable technique, and a large number 
of antibodies effective in formalin fixed paraffin embedded (FFPE) tissues and able to recognize 
different domains, either in native, or phosphorylated forms of the receptor are commercially available. 
The selection of the antibody should be based on the specific aim of the investigation: some antibodies 
recognize residues near the N-terminus of cMET, while others recognize residues near the C-terminus. 
For instance, if cMET detection is used to identify patients eligible for treatment with a monoclonal 
antibody, which blocks the receptor activity by targeting the extracellular domain of cMET, then an 
antibody directed against residues near the N-terminus should be used. Moreover, some antibodies 
match the non-phosphorylated domain of the protein, while others recognize only the phosphorylated 
form. The former are useful to measure the amount of mature protein, while the latter are useful to 
evaluate the activated form. 
A consensus on the evaluation criteria of the IHC results has not been reached yet. Literature data 
are scant, and, usually, criteria used for the assessment of other biomarkers (e.g., estrogen receptors, 
HER2, EGFR) in breast, gastric, or lung carcinoma, are extended to the evaluation of cMET 
expression in CRC. A semi-quantitative assessment—the H-score—has been described [60–62]. The 
original concept of the H-score [60] combines staining intensity (scored from 0 to 4) with the 
percentage of positive cells (scored 0%–100%). Each single intensity level is multiplied by the 
percentage of cells, and all values are summed up to obtain the final IHC score, which ranges from 0 to 
400. Scores from 0 to 200 are considered to be associated with negative/low expression, while scores 
from 201 to 400 are considered to show positive/high expression [60–62]. A modified H-score system 
has also been developed [63]. In this scoring system, three staining intensity levels (scored from 0 to 3) 
are considered. This modified H-scoring system provides a total score ranging from 0 to 300; cases are 
classified as negative (score 0–50), weakly positive (51–100), moderately positive (101–200), or 
strongly positive (201–300) [63]. Another method used to evaluate the expression of cMET is similar 
to that applied to HER2. More specifically, samples are classified as negative (0, 1+), when no staining 
or faint staining is present in <10% of cells; ambiguous (2+) when moderate staining is present in >10% 
of cells; positive (3+), when a circumferential, basolateral, or lateral signal for cMET over-expression of 
protein with strong intensity is present in >10% of the cells [64]. 
Although IHC is the most commonly-used method to examine cMET expression, it cannot establish 
whether the receptor over-expression is actually due to gene amplification or to other mechanisms, 
such as transcriptional activation or hypoxia [65]. To assess the amplification of MET, in situ 
hybridization techniques should be performed. Both fluorescence in situ hybridization (FISH) and 
single or double silver in situ hybridization (SISH) enable the measurement of the number of gene 
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copies and of the chromosome 7 centromere copy number. MET amplification can be defined 
according to what established for HER2 testing [66], in which amplification is defined as a  
gene-to-centromere ratio (MET/CEP7) ≥2.2 or MET copy number ≥6. Alternatively, the method 
described for EGFR [61] is still used to evaluate the MET status [67]. Amplification of MET is 
classified into six groups as follows: (i) disomy (≤2 copies in ≥90% of cells); (ii) low trisomy  
(≤2 copies in ≥40% of cells, 3 copies in 10%–40% of cells, ≥4 copies in <10% of cells); (iii) high 
trisomy (≤2 copies in ≥40% of cells, 3 copies in ≥40% of cells, ≥4 copies in <10% of cells); (iv) low 
polysomy (≥4 copies in 10%–40% of cells); (v) high polysomy (≥4 copies in ≥40% of cells); and  
(vi) gene amplification (defined by the presence of tight MET clusters and a ratio of MET/CEP7 ≥2, or 
≥15 copies of MET/cell in ≥10% of analyzed cells). High polysomy and gene amplification are 
considered as a positive SISH result, while the others represent negative results. 
5. MET and the Pathogenesis of Colorectal Cancer 
The role of MET in the pathogenesis of CRC has been extensively described [68–72]. The 
measurement of the expression of MET mRNA and related cMET protein in CRC can vary according 
to the technique used and to the number of samples analyzed. Results range between 30% and 91% 
with Northern blot and polymerase chain reaction (PCR) assays, and between 57% and 100% by 
Western blot and IHC analyses [73–75]. 
Most of the reports are consistent in showing that cMET expression is higher in the metastases than 
in the primary tumor tissue. Zeng et al. [72] compared MET gene copies in normal tissues, primary 
CRC, and liver metastases, by using highly quantitative PCR/ligase detection reaction technique.  
No differences between normal colonic mucosa and liver parenchyma were observed; however an 
increase in MET expression was reported in primary CRC compared with normal mucosa, and in liver 
metastases compared with normal liver tissue. Interestingly, a significant increase in cMET copies was 
observed in liver metastases compared with primary CRC tumors (18% vs. 2%, p < 0.001), suggesting 
that the amplification of this gene is a late event in CRC progression and is associated with 
hematogenous dissemination. Therefore, while MET amplification may be a rare event in localized 
CRC, it is more common in advanced tumor stages [72]. 
Di Renzo et al. [73] studied the changes of MET gene expression during the progression of CRC 
from adenoma to metastatic cancer. Overexpression was detectable in about 50% of tumors, at any 
stage of progression—although it was associated with MET amplification in only 10% of primary 
cancers, but in most cases of the metastatic tumors. This evidence suggested that MET amplification 
appears to give a selective advantage for the acquisition of metastatic phenotype and may be a late 
event in the progression of CRC [73]. 
Despite the increasing knowledge of the molecular bases of CRC progression, the exact 
mechanisms that trigger the metastatic spread are not fully understood. It has been recently observed 
that the pathways, which regulate the EMT, act as key mediators of the metastatic processes [74]. 
HGF/cMET axis may regulate the expression of E-cadherin, N-cadherin, and extracellular matrix 
degrading proteases, thus facilitating the invasiveness of tumor cells [76]. The metastasis-associated in 
colon cancer 1 (MACC1) gene has been recently described [77]. MACC1 expression was reported to be 
markedly up-regulated in all stages of both primary CRC and distant metastases tissues, when 
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compared with normal tissues. This biomarker may therefore represent an accurate prognostic 
indicator for the development of metastases. As the MET gene is a transcriptional target of MACC1, 
this latter may confer malignant potential and aggressiveness to CRC cells, thanks to its influence on 
the HGF/cMET pathway and on the MAPK axis [78]. In addition, MACC1 promotes proliferation, 
invasion and HGF-induced scattering of CRC cells in vitro, as well as tumor growth and metastases 
formation in mouse xenograft models [77]. 
6. MET-Targeting by MicroRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22–25 nucleotides that have 
emerged as critical regulators of gene expression by RNA interference. They are actively involved in 
many biological processes and play an important role in a number of diseases, including cancer [79]. 
In fact, each miRNA can target several genes and, in most cases, they are expressed in a tissue-specific 
manner. The expression of these molecules is deregulated in cancer cells compared with normal 
tissues, and experimental data showed that cancer phenotypes can be modified by targeting miRNA 
expression [80]. These findings have prompted researchers to develop miRNA-based anticancer 
therapies, which can consist in the blockade of miRNA expression in case of oncogenic miRNAs, or, 
on the other hand, in the replacement of malfunctioning or absent tumor suppressor miRNAs through 
the use of synthetic oligonucleotides (miRNA mimics) or virus-based constructs.  
However, miRNA therapy still faces many issues, including tissue-specific delivery, poor cellular 
uptake of mimics, and potential off-target effects. In order to overcome these problems, efforts should 
be taken in developing new delivery methods or in maximizing target specificity. 
Several miRNAs have been identified which target MET oncogene, including miR-34a, miR-199, 
miR-206, and miR-1 that could be challenged in therapies for silencing MET. We have recently 
observed that miR-1 is downregulated in CRC with respect to matched normal tissues and we have 
demonstrated that this miRNA can downregulate MET expression in vitro CRC models. In addition, 
re-expression of miR-1 in CRC cell lines leads to MET-driven reduction in cell proliferation and 
motility, thus suggesting that miR-1 can be a possible candidate for clinical trials of MET inhibitors in 
the treatment of metastatic CRC [70]. 
7. cMET as Prognostic Biomarker 
Lee et al. [81] demonstrated that the expression patterns of RON and cMET, as assessed by IHC, 
were significantly associated with clinical outcome in patients with CRC. In particular, the results of 
their study showed that patients whose specimens presented high expression of cMET and RON had 
an 11-fold increased risk of tumor recurrence if compared to patients with specimens showing a low 
expression [81]. 
Since MET is associated with the progression and aggressiveness of CRC [68], several studies 
suggested a role for this gene as a prognostic biomarker, given also that an increased expression of 
cMET mRNA had already been observed in highly-metastatic cell lines [82]. Moreover, in vivo studies 
reported a correlation between cMET overexpression and TNM stage, and showed a significant 
increase in cMET according to tumor size and aggressiveness in primary CRC [75,83].  
Takeuchi et al. [68] demonstrated that the overexpression of cMET increases according to the 
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invasiveness of the primary CRC and to the presence of lymph node metastases [68]. A significant 
increment in the number of cMET mRNA copies was shown in early stages CRC (T1–T2), as 
compared with more advanced ones (T3–T4). In N1–N2 tumors, the mRNA copy number was also 
increased compared with N0 tumors (p < 0.03). These data suggest that cMET overexpression plays an 
important role in the development of loco-regional invasiveness in the early stages of CRC 
development [68]. Notably, these results are in line with the finding that higher serum preoperative 
levels of HGF are associated with poor survival in stage II-III CRC [32]. 
In CRC, the activation of HGF/cMET signaling pathway is not related to gene mutation but can 
occur either in a ligand-dependent manner or through a paracrine mechanism. Kammula et al. [69] 
demonstrated that the expression levels of both cMET and HGF mRNA significantly increased from 
the normal colonic mucosa to the matched primary tumors. Noteworthy, a multivariate model was 
designed to correlate the presence of HGF and/or cMET with outcome, showing that overexpression of 
cMET and/or HGF was independently associated with poorer overall survival. 
Interestingly, in a study on resected CRC liver metastases, Osada et al. [84] measured the 
expression of cMET by Western blot analysis, as well as serum HGF levels. Results revealed that 
patients with high cMET expression in their tumors and high serum HGF levels had an increased risk 
of recurrence immediately after hepatectomy, resulting in an overall unfavorable prognosis [84]. 
Recently, in vitro studies showed that the irradiation of rectal cancer tumor cells induces an  
up-regulation of HGF expression and EMT. The subsequent production of cMET and the activation of 
its related pathway eventually boost the incidence of local and distant recurrence. In this regard, the 
inhibition of the HGF/cMET pathway may, therefore, represent a valid therapeutic approach for rectal 
cancer patients treated with preoperative chemoradiation, as it could potentially improve outcome by 
decreasing radiation-induced HGF up-regulation and metastatic potential [71]. 
In line with what has been previously done for breast cancer, a molecular classification has been 
recently proposed for CRC. Although a consensus has not been reached, Simon et al. [85] proposed a 
classification based on gene expression patterns. Data of 188 stage I-IV CRC patients were used to 
develop a molecular subtype classification, which was then validated in 543 stage II and III patients. 
The correlation with clinical characteristics and outcome was investigated and three major subtypes 
were identified (A, B, and C), based on biological features: deficiency in mismatch repair genes, 
epithelial proliferation, and EMT [85]. The subtype C was associated with the worst outcome, being 
characterized by an expression of mesenchymal genes—such as MET—and absence of benefit from 
adjuvant chemotherapy. On the other hand, a better clinical outcome was associated with A-type and 
B-type tumors, characterized by a more proliferative and epithelial phenotype, and expected benefit 
from adjuvant chemotherapy [85]. Another recent study investigated the association between c-Met 
expression and clinico-pathological characteristics on 590 CRC samples. MET overexpression was 
found in 17% of CRC tumors and was significantly associated with the gene expression of an EMT 
phenotype and a worse survival (HR 2.92; 95% CI: 1.45–5.92) [86]. 
8. cMET as Predictive Biomarker 
Although anti-EGFR MoAbs cetuximab and panitumumab have established efficacy in advanced 
CRC, they achieve a response rate of only 10%–20% when used as a single agent in unselected  
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chemo-refractory patients [87,88]. KRAS mutational status is the main predictor of primary  
resistance [89,90]. Similarly, mutations of other downstream effectors like NRAS, BRAF, or PIK3CA 
may affect response to cetuximab or panitumumab [91,92]. Indeed, the selection of patients with 
KRAS, NRAS, BRAF, and PIK3CA wild type tumors may achieve a response rate exceeding 40%. 
Unfortunately, patients who initially respond will eventually progress within three to 12 months, 
because of secondary resistance mechanisms [87,88]. 
Other mechanisms of resistance to anti-EGFR therapy may be represented by the activation of 
parallel pathways, such as HGF/cMET. It has been already established that MET amplification is a 
mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC harboring 
EGFR activating mutations [46,93]. Some emerging evidence suggest that amplification or 
overexpression of MET can play an important role for primary and secondary resistance to anti-EGFR 
therapy also in advanced CRC. In fact, in preclinical models, CRC cell lines with KRAS, BRAF, 
NRAS, and PIK3CA wild-type status developed resistance to cetuximab and panitumumab when 
ectopic cMET overexpression was induced by cDNA transfection. Experiments on xenografts derived 
from patients not exposed to anti-EGFR moAbs showed that treatment with cetuximab was not 
effective in mice engrafted with CRC specimens carrying MET amplification, suggesting that MET 
amplification may be involved in primary resistance [64]. Although rare, constitutional MET 
amplification characterizes a significant fraction of cetuximab-resistant cases that are wild type for 
KRAS, BRAF, NRAS, and PIK3CA. A previous retrospective study showed that MET overexpression 
in specimens obtained before starting treatment was associated with lack of benefit from cetuximab [94]. 
However, data from other series are conflicting, and given the low prevalence of MET amplification or 
overexpression in untreated metastatic CRC, its clinical validation as a predictive biomarker will 
require larger studies [95]. 
Recent data suggest that secondary KRAS mutations arising during treatment are responsible for 
about half cases of acquired resistance [96]. In the remaining cases, however, different mechanisms of 
resistance should be investigated. Bardelli and colleagues performed molecular analysis on tissue 
samples obtained before treatment with anti-EGFR moAbs and at the time of disease progression. In 
patients not developing KRAS mutations, the amplification and consequent overexpression of cMET 
was one of the most frequently mechanisms of acquired resistance observed. In some patients, rare 
MET-amplified cells may be found in tissue samples before treatment, suggesting that EGFR-targeted 
therapies may act as a selective pressure to expand a preexisting subclonal population of cancer cells 
with MET amplification in a Darwinian fashion [64]. 
Another mechanism for MET-induced resistance to anti-EGFR therapy is represented by its 
activation by the ligand—namely HGF. In preclinical models, stimulation with HGF is able to rescue 
cetuximab-sensitive CRC cell lines from EGFR inhibition in a dose-dependent manner through  
MET-induced activation of the AKT and MAPK pathways, even in absence of MET amplification [47]. 
These findings support the hypothesis that HGF overexpression by cancer cells themselves or by the 
surrounding stroma may be an independent mechanism of resistance to anti-EGFR therapy.  
HGF/cMET axis seems to play an important role in primary and acquired resistance to anti-EGFR 
moAbs in advanced CRC. Above all, cMET is a druggable target and cMET inhibition represents a 
promising strategy to overcome resistance. In fact, the high prevalence of activated HGF/cMET 
pathway in human malignancies has driven a rapid growth of oncology drug-development programs, 
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with several new agents targeting cMET in ongoing clinical trials [97]. These agents include the are 
summarized in Table 2 and described in the next sections: 
Table 2. Mesenchymal-epithelial transition (MET) inhibitors evaluated in clinical trials. 
Company Compound Mechanism of action Clinical development
Amgen Rilotumumab HGF IgG2 Mab Phase II:CRC 
Aveo Ficlatuzumab HGF IgG1 Mab Phase II: NSCLC 
Genetech/Roche Onartuzumab MET IgG1 Mab 
Phase II: NSCLC 
Phase II: CRC 
Pfizer Crizotinib 
MET TKI 
Other TKI inhibition: ALK, RON, AXL, TIE2 
Phase IV: NSCLC 
GlaxoSmithKline Foretinib 
MET TKI 
Other TKI inhibition: VEGFR2, AXL, PDGFR, KIT, FLT3, TIE2 
Phase II:  
Exelis Cabozantinib 
MET TKI 
Other TKI inhibition: VEGFR2, RET, KIT, FLT3, TIE2 
Phase II: NSCLC 
 
ArQule Tivantinib MET TKI Phase II:CRC 
Abbreviations: CRC, colon rectal cancer; NSCLC, non-small-cell lung cancer; RON, macrophage-stimulating protein 
receptor; PDGFR, platelet-derived growth factor receptor; TIE2, angiopoietin 1 receptor. 
8.1. Anti-HGF Monoclonal Antibodies 
AMG 102 (Rilotumumab, Amgen, Thousand Oaks, CA, USA) is a humanized monoclonal antibody 
directed against HGF, which blocks the interaction between HGF and cMET [98]. A randomized phase 
Ib/II trial of panitumumab in combination with rilotumumab or placebo was carried out for patients 
with KRAS wild-type, advanced CRC [99]. The recommended phase II doses were the standard dose 
of panitumumab and 10 mg/kg of rilotumumab biweekly. A total of 142 patients were included in the 
expansion phase II cohort of the study after failure of prior first line irinotecan- and/or oxaliplatin-based 
regimens. The response rate—namely the study primary endpoint—was 31% of patients in the 
combination arm vs. 21% in the panitumumab plus placebo arm. The median duration of response with 
the experimental arm was 5.1 months compared with 3.7 months for panitumumab alone. Median PFS 
showed a trend for improvement in the combination treatment at 5.2 months compared with  
3.7 months in the panitumumab-placebo arm [100]. Expression of cMET was measured by IHC on 
archival tumor samples, which were scored for cMET expression with a staining intensity between  
0 and 3; to determine the percentage of tumor cells expressing cMET in a sample, tumor cells with a 
staining intensity of at least 1 were considered positive—with positive tumor cells >50% considered as 
high cMET expression. However, the statistical interaction between cMET expression and treatment 
arm was not significant—probably due to small sample size and the method of IHC assessment. 
Currently, there is no development program of rilotumumab in advanced CRC, although a better 
selection of cMET positive tumors and the evaluation of rilotumumab as single agent in both KRAS 
wild-type and mutated tumors could improve the therapeutic index of this agent. Moreover, this agent 
continues to be evaluated in other malignancies, reaching phase III development in gastric cancer. 
AV-299 (Ficlatuzumab, AVEO, Cambridge, MA, USA) is a monoclonal antibody directed against 
HGF and is currently being developed in NSCLC [101]. 
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8.2. Anti-MET Monoclonal Antibodies 
MetMAb (Onartuzumab, Genentech, San Francisco, CA, USA) is a monovalent monoclonal 
antibody directed against cMET, which prevents HGF from binding to the cMET receptor and, 
ultimately, blocks ligand-induced cMET dimerization and intracellular domain activation. Of note, this 
drug was developed as a single-armed humanized modified anti-MET antibody, which acts as a 
monovalent antibody to avoid agonistic activity that may occur when a bivalent antibody binds to two 
separate cMET molecules [102]. In CRC, a phase II randomized study of onartuzumab versus placebo, 
both in association with the standard of fist-line treatment (modified FOLFOX-6 plus bevacizumab) 
was recently closed to enrollment with the primary endpoint of detecting progression-free survival 
differences [103]. The evaluation of cMET is a pre-specified retrospective analysis that will be carried 
out using the same criteria described by Spiegel et al. [104] for NSCLC. Briefly, intensity of MET 
staining on tumor cells will be scored in four categories: negative, weak, moderate, and strong. MET 
positivity will be defined as the majority (≥50%) of tumor cells with a moderate or strong staining 
intensity. Currently, the final results of the phase II CRC study are pending. 
8.3. Tyrosine Kinase Inhibitors 
TKIs are small molecules, which compete for the adenosine triphosphate binding site in the tyrosine 
kinase domain of cMET, thus preventing receptor transactivation and recruitment of downstream 
effectors. They can be classified as unselective or selective inhibitors. 
Among unselective TKIs, crizotinib (PF-02341066; Pfizer, New York, NY, USA) is an orally 
available 2-amino-3-benzyloxy-5-arylpyridine compound, initially developed to target cMET. After 
the discovery of the anaplastic lymphoma kinase (ALK), it was renamed as the ALK-targeted therapy, 
which was approved by the US Food and Drug Administration for patients with NSCLC harboring 
EML4-ALK gene rearrangement [105]. 
Foretinib (XL 880, EXEL 2880, GSK 1363089; Exelixis/GlaxoSmithKline, Philadelphia, PA, 
USA) is an oral multikinase inhibitor developed to target cMET and several other tyrosine kinases 
involved in angiogenesis. It is an ATP-competitive inhibitor and binds to the ATP pocket of cMET and 
VEGFR-2 tyrosine kinase domains (dual VEFGR-2/cMET inhibitor) [106]. 
Cabozantinib (XL-184/BMS-907351; Exelixis, South San Francisco, CA, USA/Bristol-Myers 
Squibb, Princeton, NJ, USA) is an orally administrated TKI, which targets cMET and VEGFR1-3. It 
can pass the blood-brain barrier and presents a marked activity in blastic bone metastases deriving 
from prostate cancer [107]. 
However, unselective cMET inhibitors such as foretinib amd cabozantinib are not currently being 
evaluated in patients with advanced CRC. 
Tivantinib (ARQ-197, ArQule (Woburn, MA, USA), in partnership with Daiichi Sankyo (Tokyo, 
Japan) and Asian licensee Kyowa Hakko Kirin (Tokyo, Japan)) is a highly-selective, oral,  
non-adenosine triphosphate (ATP)-competitive cMET inhibitor. A phase I/II randomized study of 
biweekly schedule of irinotecan and cetuximab associated with tivantinib or placebo was conducted 
after failure of first line therapy for patients with KRAS wild-type advanced CRC [108]. At the 
recommended phase II dose of tivantinib (360 mg twice daily), the investigational drug failed to show 
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any statistically significant improvement of the primary endpoint—progression-free survival—as 
median time was 8.3 months in tivantinib arm vs. 7.3 months in the placebo arm (hazard ratio 0.85, 
95% confidence interval, 0.55–1.33; p = 0.38) [109]. There appeared to be some benefit for PFS in the 
subgroup that received previous first-line oxaliplatin-based treatment. However, this advantage was 
obtained from a retrospective subgroup analysis and was not statistically significant (hazard ratio 0.66 
with a confidence interval of 0.41–1.09). 
Finally, INCB028060, PF-04217903, E7050, JNJ-38877605, and BMS-777607 are potent and 
selective inhibitors of cMet receptor tyrosine kinase and completed the first in human studies. 
9. Conclusions 
MET is considered a promising prognostic biomarker in early stage CRC. In advanced disease, the 
potential predictive role of MET for benefit from molecularly targeted agents will be explored, and 
hopefully confirmed, by prospective studies. The optimal methods of assessment of cMET as 
biomarkers are still being developed. As a result, patient selection in current and prior studies has been 
underemphasized. For future analyses, a strong recommendation for a select patient population should 
be encouraged based on biomarker data, since this is more likely to be representative of tumor biology 
and the therapeutic potential of targeted therapies. Thus far, most studies have assessed the 
HGF/cMET axis in tumors at baseline. However, HGF/cMET activation has been implicated as an 
important mechanism of metastatic progression and treatment resistance. Future studies should address 
the need to biopsy the most recent site of metastatic progression, since targeted therapy directed 
against HGF/cMET may be of considerable value in surmounting both primary and acquired resistance 
in selected CRC populations [110]. 
In this regard, MET could be a “mixed” biomarker—with negative prognostic value and positive 
predictive effect. However, the potential application of MET routine assessment in the clinical practice 
will strongly be dependent on the possibility to conduct adequately powered, biomarkers-driven 
clinical trials with the goal of personalized medicine. 
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